Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice
Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of i...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 14, 2017
|
| In: |
Cancer research
Year: 2017, Volume: 77, Issue: 6, Pages: 1250-1260 |
| ISSN: | 1538-7445 |
| DOI: | 10.1158/0008-5472.CAN-16-2179 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1158/0008-5472.CAN-16-2179 Verlag, kostenfrei, Volltext: http://cancerres.aacrjournals.org/content/77/6/1250 
|
| Author Notes: | Bernard Leroy, Mandy L. Ballinger, Fanny Baran-Marszak, Gareth L. Bond, Antony Braithwaite, Nicole Concin, Lawrence A. Donehower, Wafik S. El-Deiry, Pierre Fenaux, Gianluca Gaidano, Anita Langerød, Eva Hellstrom-Lindberg, Richard Iggo, Jacqueline Lehmann-Che, Phuong L. Mai, David Malkin, Ute M. Moll, Jeffrey N. Myers, Kim E. Nichols, Sarka Pospisilova, Patricia Ashton-Prolla, Davide Rossi, Sharon A. Savage, Louise C. Strong, Patricia N. Tonin, Robert Zeillinger, Thorsten Zenz, Joseph F. Fraumeni, Peter E.M. Taschner, Pierre Hainaut, and Thierry Soussi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 158012657X | ||
| 003 | DE-627 | ||
| 005 | 20220814223157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180816s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-16-2179 |2 doi | |
| 035 | |a (DE-627)158012657X | ||
| 035 | |a (DE-576)51012657X | ||
| 035 | |a (DE-599)BSZ51012657X | ||
| 035 | |a (OCoLC)1341017187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Leroy, Bernard |e VerfasserIn |0 (DE-588)1164726749 |0 (DE-627)1029014434 |0 (DE-576)510126472 |4 aut | |
| 245 | 1 | 0 | |a Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice |c Bernard Leroy, Mandy L. Ballinger, Fanny Baran-Marszak, Gareth L. Bond, Antony Braithwaite, Nicole Concin, Lawrence A. Donehower, Wafik S. El-Deiry, Pierre Fenaux, Gianluca Gaidano, Anita Langerød, Eva Hellstrom-Lindberg, Richard Iggo, Jacqueline Lehmann-Che, Phuong L. Mai, David Malkin, Ute M. Moll, Jeffrey N. Myers, Kim E. Nichols, Sarka Pospisilova, Patricia Ashton-Prolla, Davide Rossi, Sharon A. Savage, Louise C. Strong, Patricia N. Tonin, Robert Zeillinger, Thorsten Zenz, Joseph F. Fraumeni, Peter E.M. Taschner, Pierre Hainaut, and Thierry Soussi |
| 246 | 3 | 0 | |a TP 53 |
| 264 | 1 | |c March 14, 2017 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online first: March 2, 2017 | ||
| 500 | |a Gesehen am 16.08.2018 | ||
| 520 | |a Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed TP53 as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 TP53 variants reveals that the two newly discovered exons of the gene, exons 9β and 9γ, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrange-ments in intron 1 of TP53 are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing TP53 status in clinical samples. Finally, we discuss how TP53 alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports. | ||
| 700 | 1 | |a Zenz, Thorsten |d 1970- |e VerfasserIn |0 (DE-588)114963738 |0 (DE-627)577184202 |0 (DE-576)180278266 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d Philadelphia, Pa. : AACR, 1941 |g 77(2017), 6, Seite 1250-1260 |h Online-Ressource |w (DE-627)325489955 |w (DE-600)2036785-5 |w (DE-576)094502226 |x 1538-7445 |7 nnas |a Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice |
| 773 | 1 | 8 | |g volume:77 |g year:2017 |g number:6 |g pages:1250-1260 |g extent:11 |a Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-16-2179 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://cancerres.aacrjournals.org/content/77/6/1250 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180816 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 114963738 |a Zenz, Thorsten |m 114963738:Zenz, Thorsten |p 27 | ||
| 999 | |a KXP-PPN158012657X |e 3022484917 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online first: March 2, 2017","Gesehen am 16.08.2018"],"language":["eng"],"recId":"158012657X","person":[{"role":"aut","display":"Leroy, Bernard","roleDisplay":"VerfasserIn","given":"Bernard","family":"Leroy"},{"family":"Zenz","given":"Thorsten","roleDisplay":"VerfasserIn","display":"Zenz, Thorsten","role":"aut"}],"title":[{"title_sort":"Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice","title":"Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"title":[{"title":"Cancer research","title_sort":"Cancer research"}],"disp":"Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practiceCancer research","note":["Gesehen am 31.03.25","Fortsetzung der Druck-Ausgabe"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"corporate":[{"display":"American Association for Cancer Research","roleDisplay":"Herausgebendes Organ","role":"isb"}],"recId":"325489955","pubHistory":["Volume 1, issue 1 (1 January 1941)-"],"part":{"text":"77(2017), 6, Seite 1250-1260","volume":"77","extent":"11","year":"2017","pages":"1250-1260","issue":"6"},"name":{"displayForm":["American Association for Cancer Research"]},"origin":[{"publisherPlace":"Philadelphia, Pa.","dateIssuedDisp":"1941-","publisher":"AACR","dateIssuedKey":"1941"}],"id":{"eki":["325489955"],"zdb":["2036785-5"],"issn":["1538-7445"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Bernard Leroy, Mandy L. Ballinger, Fanny Baran-Marszak, Gareth L. Bond, Antony Braithwaite, Nicole Concin, Lawrence A. Donehower, Wafik S. El-Deiry, Pierre Fenaux, Gianluca Gaidano, Anita Langerød, Eva Hellstrom-Lindberg, Richard Iggo, Jacqueline Lehmann-Che, Phuong L. Mai, David Malkin, Ute M. Moll, Jeffrey N. Myers, Kim E. Nichols, Sarka Pospisilova, Patricia Ashton-Prolla, Davide Rossi, Sharon A. Savage, Louise C. Strong, Patricia N. Tonin, Robert Zeillinger, Thorsten Zenz, Joseph F. Fraumeni, Peter E.M. Taschner, Pierre Hainaut, and Thierry Soussi"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"March 14, 2017"}],"id":{"eki":["158012657X"],"doi":["10.1158/0008-5472.CAN-16-2179"]}} | ||
| SRT | |a LEROYBERNARECOMMENDE1420 | ||